A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.

[1]  G. Giaccone,et al.  Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study , 2006, Clinical Cancer Research.

[2]  W. Enker,et al.  Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[4]  J. Shih,et al.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Zou,et al.  EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer , 2009, Cancer.

[6]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[7]  A. Senagore,et al.  Molecular staging of colorectal cancer , 2000, Diseases of the colon and rectum.

[8]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[9]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Ariza,et al.  K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. , 1994, Lung cancer.

[12]  A. Ardizzoni,et al.  Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  M. Ho,et al.  Clinicopathological Features and Prognosis in Resectable Synchronous and Metachronous Colorectal Liver Metastasis , 2007, Annals of Surgical Oncology.

[14]  G. Fontanini,et al.  Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[16]  S. Petersen,et al.  Towards a Genetic-Based Classification of Human Lung Cancer , 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[17]  A. Italiano,et al.  Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[19]  L. Bubendorf,et al.  Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers , 2007, British Journal of Cancer.

[20]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Varella‐Garcia,et al.  Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay , 2006, Diagnostic pathology.

[22]  S. Dacic,et al.  Patterns of Allelic Loss of Synchronous Adenocarcinomas of the Lung , 2005, The American journal of surgical pathology.

[23]  S. Petersen,et al.  Chromosomal imbalances of primary and metastatic lung adenocarcinomas , 2002, The Journal of pathology.

[24]  J. Luketich,et al.  Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. , 2006, American journal of clinical pathology.

[25]  I. Wistuba,et al.  Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas , 2008, Cancer Prevention Research.

[26]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[27]  V. Seshan,et al.  Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  H. Ueno,et al.  Indicators for treatment strategies of colorectal liver metastases. , 2000, Annals of surgery.

[29]  S. Veronese,et al.  Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Schwartz,et al.  KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression , 2007, Oncogene.

[31]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[32]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Ladanyi,et al.  Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. , 2009, Archives of pathology & laboratory medicine.

[34]  J. Minna,et al.  Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[35]  E. Gabrielson.  Worldwide trends in lung cancer pathology , 2006, Respirology.

[36]  Xiao-Cheng Wu,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control , 2008, Journal of the National Cancer Institute.

[37]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[38]  E. Stathopoulos,et al.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC , 2008, British Journal of Cancer.

[39]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[40]  G. Giaccone,et al.  Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  M. Nordberg,et al.  EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens , 2007, Modern Pathology.

[42]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[43]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[44]  W. Schlegel,et al.  Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Rodenhuis,et al.  Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.

[46]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Y. Ishikawa,et al.  Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. , 2007, Chest.

[48]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[49]  E. Raso,et al.  Phenotype of bone metastases of nonsmall cell lung cancer: Epidermal growth factor receptor expression and KRAS mutational status , 2008, Pathology & Oncology Research.

[50]  A. Sapino,et al.  Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens , 2007, Molecular Cancer Therapeutics.